EU Report Probes Impact Of IP Incentives On R&D, Market Access

 
• By Ian Schofield

A report for the European Commission’s analysis of pharmaceutical IP incentives finds that the effective protection period has declined over 20 years, but delays to generic entry are still putting pressure on pharmaceutical spending.

Scales
An EU report looks at the balance of IP incentives and medicines access

More from Legal & IP

More from Pink Sheet